Drug intelligence / Profile preview

adeno-associated virus tRNA glycine

Development stage
Preclinical
Lead developer
XtRNA Bio
Modality
Gene Therapies
Administration
Intravenous, Intrathecal
01

Overview

adeno-associated virus tRNA glycine (AAV-tRNA-Gly) is an investigational gene therapy designed to treat Charcot-Marie-Tooth disease type 2D (CMT2D), a progressive neuromuscular disorder. CMT2D is caused by dominant mutations in the GARS1 gene, which encodes glycyl-tRNA synthetase (GlyRS). The mutant GlyRS enzyme binds to tRNA Gly with abnormally high affinity and fails to release it, leading to tRNA Gly sequestration, ribosome stalling, activation of the integrated stress response (ISR), and axonal degeneration. Developed by XtRNA Bio (a spinout from Radboud University), AAV-tRNA-Gly utilizes an adeno-associated virus vector to deliver genetic instructions that elevate cellular tRNA Gly levels. This supplementation restores normal protein synthesis, suppresses ISR activation, and has been shown in preclinical models to prevent and reverse peripheral neuropathy.

Other names
AAV-tRNA GlyAAV-tRNA-GlyAAV.PHP.S-tRNA GlyAAV.PHP.eB-tRNA GlyAAV9-tRNA GlyAAV-9-tRNA GlyAAV 9-tRNA Glyglycyl-tRNA gene therapytRNA Gly gene therapy
02

Targets

Beyond the preview

Go deeper on adeno-associated virus tRNA glycine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on adeno-associated virus tRNA glycine.

Work on adeno-associated virus tRNA glycine? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call